查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1922935

按藥物類別、給藥途徑、治療方法、分銷管道和最終用戶分類的直接抗病毒藥物市場—2026-2032年全球預測

Direct Acting Antivirals Market by Drug Class, Route Of Administration, Treatment Regimen, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，直接作用抗病毒藥物市場價值將達到 489.1 億美元，到 2026 年將成長至 523.7 億美元，複合年成長率為 8.13%，到 2032 年將達到 845.6 億美元。

關鍵市場統計數據
基準年 2025 489.1億美元
預計年份：2026年 523.7億美元
預測年份 2032 845.6億美元
複合年成長率 (%) 8.13%

對直接抗病毒藥物生態系統進行策略性介紹，重點在於治療突破、市場准入趨勢、監管里程碑和相關人員的優先事項。

直接抗病毒藥物（DAAs）重新定義了慢性C型肝炎的臨床治療方案，建立了標靶感染治癒性治療的新典範。過去十年，臨床療效已從緩慢的病毒抑制轉變為高且持續的病毒學反應率，從而實現了治療方法更短、耐受性更好，並最大限度地減輕了長期疾病負擔。隨著臨床療效的提升，監管機構也改善了聯合治療的核准流程，促進了品牌藥和學名藥的上市，並提高了不同醫療體系中患者的治療可及性。

治療創新、分散式醫療服務、數位化轉型和供應鏈重組如何重塑直接抗病毒藥物（DAA）市場格局和相關人員的策略

直接抗病毒藥物（DAA）領域正經歷著變革性的轉變，這主要得益於治療創新、供應鏈重組以及醫療服務模式的演變。在臨床上，泛基因型治療方法和固定劑量組合藥物的出現簡化了治療流程，並減少了對廣泛基因分型檢測的需求。更短的療程和更高的耐受性擴大了患者群體，並將醫療服務下放至基層醫療和社區醫療機構。同時，真實世界數據和核准後安全性數據正在為治療方法的迭代調整提供資訊，並增強支付方對治療結果的信心。

評估2025年美國關稅如何改變了DAA供應鏈的採購、製造地和商業合約動態

自2025年起實施的美國關稅政策，其累積影響已波及抗病毒療法的採購慣例、供應商選擇和製造地。某些藥品成分關稅的提高，導致活性藥物成分（API）和複雜輔料的短期成本上升，迫使採購團隊重新評估供應商合約和物流路線。為此，許多製造商加快了API和製劑生產的多元化進程，將生產分散到多個司法管轄區，以降低關稅風險和運輸瓶頸。這促使他們更加重視地域多角化和雙重採購策略。

細分分析洞察：揭示藥物類別、通路、給藥途徑和治療方法結構對臨床、商業性和營運的影響

細分市場分析按藥物類別、分銷管道、最終用戶、給藥途徑和治療方法，深入剖析了臨床和商業性機會。依藥物類別分類，市場細分為 Ns3/4A 蛋白酶抑制劑、Ns5A 抑制劑和 Ns5B聚合酵素抑制劑。 Ns3/4A 蛋白酶抑制劑又可細分為格卡瑞韋 (glecaprevir) 和伏西瑞韋 (voxilaprevir) 等藥物；Ns5A 抑制劑則以聯合治療為主，例如雷迪帕韋-索非布韋 (ledipasvir-sofosbuvir) 和維帕Velpatasvir韋-索非亞布韋( Dasabuvir)及索非布韋 (sofosbuvir) 為代表。每類藥物都有其獨特的抗藥性特徵、藥物交互作用考量和處方集定位，這些因素都會影響治療方法的選擇和臨床路徑的設計。

影響全球主要地區准入策略、生產決策和支付方參與的區域臨床、監管和商業性趨勢

區域趨勢正在影響不同地區的藥品取得、生產策略和支付方參與。在美洲，先進的支付方框架和集中化的生產能力推動了簡化治療方法的快速普及，而地方政府層面的藥品獲取差異則需要有針對性的定價和准入計劃。在歐洲、中東和非洲地區，監管多樣性和不同的採購機制既構成了挑戰，也帶來了機會。一些地區的集中採購與其他地區的分散市場結構形成鮮明對比，這需要量身定做的市場進入策略和公私合營。在亞太地區，高發地區、強大的學名藥生產基地和先進的公共衛生項目並存，形成了一個競爭激烈的定價、以競標為導向的競標和創新應用並存的複雜環境。

藥物研發策略、非專利競爭和策略聯盟如何重塑產品系列優先事項、生產聯盟和商業性管理

在直接授權學名藥（DAA）市場，企業層級的行為呈現出品牌藥生產商的監管、非專利競爭和策略聯盟三者並存的局面。品牌藥生產商優先考慮智慧財產權管理、透過配方改善延長產品生命週期以及提供全面的實證醫學證據，以維持其高階市場地位。同時，非專利生產商和授權非專利項目則利用本地化生產和簡化的監管途徑，在價格敏感的市場環境中提供價格更實惠的替代藥物，並擴大患者的用藥範圍。策略聯盟、授權協議和聯合行銷協議已成為協調全球監管要求與本地商業化能力的常用機制。

切實可行的策略性舉措，旨在加強供應鏈韌性，推動以患者為中心的藥物研發，並使商業模式與支付方和醫療系統優先事項保持一致。

業界領導者可以採取切實可行的措施，在保障病人用藥的同時，維持商業性的永續性。首先，透過拓展原料藥（API）和成品藥的生產，涵蓋多個地區，並對二級供應商進行資格認證，從而增強供應鏈韌性，最大限度地減少中斷。其次，優先開發固定劑量組合藥物和有助於提高患者依從性的配方，以降低臨床複雜性，並支持分散式醫療模式。第三，積極與支付方和醫療系統合作，透過真實世界數據、衛生經濟學模型以及將臨床獲益與預算優先事項相結合的基本契約，展現產品的長期價值。

結合臨床文獻、監管審查、專家訪談和供應鏈分析等多方面透明研究方法，得出可操作的結論。

本研究採用多面向方法，整合多種資訊來源，確保研究結果嚴謹且具可操作性。調查方法包括：系統性回顧臨床文獻、分析監管核准和附加檔變更、檢驗產品處方集和分銷管道結構，以及繪製製造地和供應鏈流程圖。此外，還對臨床專家、供應鏈經理和商業負責人進行了結構化訪談，以補充二手訊息，從而更好地理解實際應用中的藥物使用模式、准入障礙和支付方獎勵。

對直接授權協議 (DAA) 的機會和策略挑戰進行簡潔扼要的總結，重點在於准入、生產韌性和基於證據的商業化。

總之，直接抗病毒藥物（DAA）是一個日益成熟的治療領域，其臨床療效、簡化的治療方法和更高的耐受性相結合，使得在人群層面控制疾病成為可能。泛基因型療法、固定劑量組合藥物和不斷擴大的分銷管道的融合，有助於擴大治療的可及性，但商業性成功需要精心協調生產策略、與支付方合作以及產品差異化特性。不斷變化的貿易政策和區域准入趨勢進一步加劇了策略環境的複雜性，因此，敏捷性和實證決策至關重要。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按藥物類別分類的直接抗病毒藥物市場

  • Ns3/4A蛋白酶抑制劑
    • 格卡瑞韋
    • 伏西拉普韋
  • Ns5A抑制劑
    • 雷迪帕韋 索非布韋
    • Velpatasvir/索非布韋
  • Ns5B聚合酵素抑制劑
    • Dasabuvir
    • 索非布韋

9. 按給藥途徑分類的直接抗病毒藥物市場

  • 固定劑量組合藥物
    • 每日一次給藥
    • 每日兩次給藥
  • 單片裝
    • 每日一次給藥
    • 每日兩次給藥

10.治療方法分類的直接抗病毒藥物市場

  • 聯合治療
    • 雙重療法
      • Ns3 4A Ns5A
      • Ns5A Ns5B
    • 三聯療法
  • 單藥治療

第11章 按分銷管道分類的直接抗病毒藥物市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 依最終用戶分類的直接抗病毒藥物市場

  • 醫院
  • 零售藥房
  • 專科診所

13. 各地區直接作用抗病毒藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 直接作用抗病毒藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國直接抗病毒藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國直接作用抗病毒藥物市場

第17章：中國直接抗病毒藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Johnson & Johnson
  • Laurus Labs Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Natco Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Pharco Pharmaceuticals
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Strides Pharma Science Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-867BED9A9E69

The Direct Acting Antivirals Market was valued at USD 48.91 billion in 2025 and is projected to grow to USD 52.37 billion in 2026, with a CAGR of 8.13%, reaching USD 84.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 48.91 billion
Estimated Year [2026] USD 52.37 billion
Forecast Year [2032] USD 84.56 billion
CAGR (%) 8.13%

A strategic introduction to the direct acting antivirals ecosystem highlighting therapeutic breakthroughs, access dynamics, regulatory milestones and stakeholder priorities

Direct acting antivirals (DAAs) have redefined the clinical approach to chronic hepatitis C and established a paradigm for targeted, infection-curing therapeutics. Over the past decade clinical outcomes have transitioned from incremental viral suppression to high sustained virologic response rates, enabling short-course, well-tolerated regimens that minimize long-term disease burden. Alongside clinical efficacy, regulatory agencies have evolved approval pathways for combination regimens, fostering both originator and generic entries while increasing treatment accessibility in diverse health systems.

From a strategic perspective, stakeholders now operate at the intersection of clinical optimization and systems-level delivery. Payers and providers are refining formulary placement and access criteria to balance clinical benefit with budgetary constraints. Manufacturers focus on formulation innovation, real-world evidence generation, and lifecycle management to sustain differentiated value. These converging forces frame the current DAA ecosystem and set the priorities for innovation, commercialization, and policy engagement going forward.

How therapeutic innovation, delivery decentralization, digital enablement and supply chain realignment are reshaping the DAA landscape and stakeholder strategies

The DAA landscape is experiencing transformative shifts driven by therapeutic innovation, supply chain reconfiguration, and evolving care delivery models. Clinically, the emergence of pan-genotypic regimens and fixed-dose combinations has simplified treatment algorithms and reduced the need for extensive genotype testing. Shorter treatment durations and improved tolerability have widened the candidate pool for therapy, enabling decentralization of care into primary and community settings. At the same time, real-world evidence and post-approval safety data have informed iterative regimen adjustments and strengthened payer confidence in curative outcomes.

Commercially, manufacturers are responding with differentiated product strategies that emphasize adherence-friendly dosing and simplified logistics. The rise of online and specialty distribution channels complements traditional hospital and retail pharmacies, offering convenience and continuity for patients. Concurrently, digital health tools and telemedicine have accelerated remote monitoring and adherence support, enabling clinicians to manage therapy outside tertiary centers. These shifts collectively reposition DAAs from specialized hospital treatments to accessible, community-delivered cures that require integrated commercial and clinical strategies.

Assessment of how the 2025 United States tariff actions have shifted procurement, manufacturing footprints and commercial contracting dynamics across the DAA supply chain

The cumulative impact of the United States tariffs introduced in 2025 has reverberated across procurement practices, supplier sourcing, and manufacturing footprints for antiviral therapies. Increased tariffs on certain pharmaceutical inputs elevated the near-term cost base for active pharmaceutical ingredients and complex excipients, prompting procurement teams to reassess supplier contracts and logistics routes. In response, many manufacturers accelerated diversification of API and finished-dose manufacturing across multiple jurisdictions to mitigate tariff exposure and shipping bottlenecks, thereby increasing emphasis on regionalization of supply chains and dual-sourcing strategies.

Beyond direct cost implications, tariff-driven adjustments altered negotiation dynamics with distributors and payers. Contracting teams sought greater clarity on landed cost and total cost of therapy, while policymakers and regulators engaged with industry to preserve therapeutic access. For product teams and commercial leaders, the tariffs underscored the importance of supply chain transparency, localized manufacturing investments, and scenario planning to avoid disruption to patient access. Ultimately, the policy environment catalyzed a shift from single-source efficiency to resilient supply architectures that prioritize continuity of supply and price stability.

Segment-driven insights revealing clinical, commercial and operational implications across drug classes, channels, administration routes and regimen architectures

Segmentation analysis reveals nuanced clinical and commercial opportunities across drug class, distribution channel, end user, route of administration, and treatment regimen. Based on drug class, the market divides into Ns3/4A Protease Inhibitors, Ns5A Inhibitors, and Ns5B Polymerase Inhibitors, with the Ns3/4A Protease Inhibitors further distinguished by agents such as Glecaprevir and Voxilaprevir, the Ns5A Inhibitors explored through combinations like Ledipasvir Sofosbuvir and Velpatasvir Sofosbuvir, and the Ns5B Polymerase Inhibitors represented by Dasabuvir and Sofosbuvir. Each class carries distinct resistance profiles, drug-drug interaction considerations, and formulary positioning, which informs regimen selection and clinical pathway design.

Based on distribution channel, comparisons among hospital pharmacy, online pharmacy, and retail pharmacy reveal divergent fulfillment models and patient touchpoints that affect adherence support and post-prescription services. Based on end user, hospitals, retail pharmacies, and specialty clinics each present different engagement models for prescribers and patients, with hospitals often handling complex cases and specialty clinics enabling focused treatment pathways. Based on route of administration, fixed dose combinations and single agent tablets-and their once-daily versus twice-daily dosing variants-shape adherence dynamics and patient preference. Finally, based on treatment regimen, combination therapy and monotherapy split into dual and triple therapy permutations, with dual therapy combinations such as Ns3/4A plus Ns5A or Ns5A plus Ns5B and triple therapy across Ns3/4A, Ns5A and Ns5B offering options for treatment-experienced or resistant populations. These segmentation lenses together guide portfolio prioritization, clinical positioning, and channel strategy for maximizing patient reach and therapeutic impact.

Regional clinical, regulatory and commercial dynamics that determine access strategies, manufacturing decisions and payer engagement across key global territories

Regional dynamics shape access, manufacturing strategy, and payer engagement across distinct geographies. In the Americas, a combination of advanced payer frameworks and concentrated manufacturing capacity drives rapid uptake of simplified regimens, while disparities in access across subnational systems demand targeted pricing and access programs. In Europe, Middle East & Africa, regulatory heterogeneity and variable procurement mechanisms create both barriers and opportunities: centralized purchasing in some jurisdictions contrasts with fragmented markets in others, necessitating tailored market access strategies and public-private collaborations. In Asia-Pacific, high prevalence pockets coexist with a strong generics manufacturing base and progressive public health programs, which together create a complex environment of competitive pricing, volume-driven tendering, and innovation adoption.

These regional contours influence strategic decisions around manufacturing localization, licensing and partnership models, and patient support infrastructure. Regulatory pathways and reimbursement criteria differ by region, so lifecycle planning must account for varied registration timelines and health technology assessment requirements. Furthermore, regional digital health adoption and telemedicine penetration affect how providers engage patients, while localized patient assistance programs and community outreach remain essential to expand treatment uptake in underserved populations.

How originator strategies, generic competition and strategic partnerships are reshaping portfolio priorities, manufacturing alliances and commercial stewardship

Company-level behavior in the DAA landscape reflects a mix of originator stewardship, generic competition, and strategic alliances. Originator firms have prioritized intellectual property management, lifecycle extensions through formulation enhancements, and comprehensive evidence generation to preserve premium positioning. Concurrently, generic manufacturers and authorized generic programs have expanded access in price-sensitive settings, leveraging local manufacturing and streamlined regulatory pathways to deliver affordable alternatives. Strategic alliances, licensing agreements, and co-marketing arrangements have become common mechanisms to reconcile global regulatory requirements with local commercialization capabilities.

Commercial leaders must balance investment in brand-differentiating activities-such as adherence support, physician education, and real-world outcome tracking-with pragmatic pricing and access initiatives in markets where generics predominate. Manufacturing partnerships and contract development and manufacturing organizations play a pivotal role in scaling supply while maintaining quality standards. Portfolio managers should monitor competitor lifecycle activities, regulatory exclusivity timelines, and partnership opportunities to optimize launch sequencing and post-launch support for combination regimens and new formulations.

Practical strategic moves to enhance supply chain resilience, accelerate patient-centric formulations and align commercial models with payer and health system priorities

Industry leaders can take specific, actionable steps to protect patient access while preserving commercial viability. First, strengthen supply chain resilience by diversifying API and finished-dose manufacturing across multiple regions and by qualifying secondary suppliers to minimize disruption. Second, prioritize fixed-dose combination development and adherence-enhancing formulations that reduce clinical complexity and support decentralized care models. Third, engage proactively with payers and health systems to demonstrate long-term value through real-world evidence, health economic modeling, and outcome-based contracting that align clinical benefit with budgetary priorities.

Additionally, invest in digital adherence solutions and telehealth-enabled care pathways to support decentralized treatment and improve cure rates. Forge targeted partnerships with local manufacturers and procurement agencies to address pricing sensitivities in lower-resource settings while protecting intellectual property through structured licensing or voluntary agreements. Finally, embed scenario planning and policy monitoring into commercial planning to respond rapidly to trade policy changes, tariff shifts, or regulatory reforms that could affect access and pricing dynamics.

A transparent, multi-method research approach combining clinical literature, regulatory review, expert interviews and supply chain mapping to underpin actionable insights

This research synthesized diverse sources and applied a multi-method approach to ensure rigorous, actionable insights. The methodology combined systematic review of clinical literature, analysis of regulatory approvals and label changes, review of product formularies and distribution channel structures, and mapping of manufacturing footprints and supply chain flows. In addition, structured interviews with clinical experts, supply chain managers, and commercial leaders supplemented secondary data to contextualize real-world adoption patterns, access barriers, and payer incentives.

Data validation included cross-referencing regulatory documents, clinical trial registries, and published safety and effectiveness studies, as well as triangulation against industry press releases and procurement announcements. Where uncertainty existed, sensitivity analyses and scenario planning informed interpretive conclusions. Limitations of the approach include reliance on publicly available documentation for certain operational details and the lag inherent in published data compared with rapid policy or contract changes, which the methodology mitigated through targeted expert consultations and continuous update checks.

Concise synthesis of DAA opportunities and strategic imperatives emphasizing access, manufacturing resilience and evidence-driven commercialization

In summary, direct acting antivirals represent a maturing therapeutic area where clinical efficacy, simplified regimens, and improved tolerability converge to enable population-level disease control. The confluence of pan-genotypic therapies, fixed-dose combinations, and expanding distribution channels supports broader treatment access, yet commercial success requires careful alignment of manufacturing strategy, payer engagement, and differentiated product features. Trade policy changes and regional access dynamics further complicate the strategic environment, making agility and evidence-driven decision-making imperative.

For stakeholders across industry, healthcare delivery, and policy, the priority is to translate clinical opportunity into sustainable access. That requires coordinated efforts to shore up supply chains, invest in formulations and adherence supports that fit decentralized care, and forge commercial agreements that reflect long-term clinical and economic value. When executed coherently, these steps will ensure the full therapeutic promise of DAAs is realized across diverse health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Direct Acting Antivirals Market, by Drug Class

  • 8.1. Ns3/4A Protease Inhibitors
    • 8.1.1. Glecaprevir
    • 8.1.2. Voxilaprevir
  • 8.2. Ns5A Inhibitors
    • 8.2.1. Ledipasvir Sofosbuvir
    • 8.2.2. Velpatasvir Sofosbuvir
  • 8.3. Ns5B Polymerase Inhibitors
    • 8.3.1. Dasabuvir
    • 8.3.2. Sofosbuvir

9. Direct Acting Antivirals Market, by Route Of Administration

  • 9.1. Fixed Dose Combinations
    • 9.1.1. Once Daily Dosing
    • 9.1.2. Twice Daily Dosing
  • 9.2. Single Agent Tablets
    • 9.2.1. Once Daily Dosing
    • 9.2.2. Twice Daily Dosing

10. Direct Acting Antivirals Market, by Treatment Regimen

  • 10.1. Combination Therapy
    • 10.1.1. Dual Therapy
      • 10.1.1.1. Ns3 4A Ns5A
      • 10.1.1.2. Ns5A Ns5B
    • 10.1.2. Triple Therapy
  • 10.2. Monotherapy

11. Direct Acting Antivirals Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Direct Acting Antivirals Market, by End User

  • 12.1. Hospitals
  • 12.2. Retail Pharmacies
  • 12.3. Specialty Clinics

13. Direct Acting Antivirals Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Direct Acting Antivirals Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Direct Acting Antivirals Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Direct Acting Antivirals Market

17. China Direct Acting Antivirals Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca plc
  • 18.8. Aurobindo Pharma Limited
  • 18.9. Bayer AG
  • 18.10. Biogen Inc.
  • 18.11. Boehringer Ingelheim International GmbH
  • 18.12. Bristol-Myers Squibb Company
  • 18.13. Cipla Limited
  • 18.14. Dr. Reddy's Laboratories Ltd.
  • 18.15. Eli Lilly and Company
  • 18.16. Gilead Sciences, Inc.
  • 18.17. GlaxoSmithKline plc
  • 18.18. Hetero Labs Limited
  • 18.19. Johnson & Johnson
  • 18.20. Laurus Labs Limited
  • 18.21. Lupin Limited
  • 18.22. Merck & Co., Inc.
  • 18.23. Natco Pharma Limited
  • 18.24. Novartis AG
  • 18.25. Pfizer Inc.
  • 18.26. Pharco Pharmaceuticals
  • 18.27. Regeneron Pharmaceuticals, Inc.
  • 18.28. Roche Holding AG
  • 18.29. Sanofi S.A.
  • 18.30. Strides Pharma Science Limited
  • 18.31. Takeda Pharmaceutical Company Limited
  • 18.32. Teva Pharmaceutical Industries Ltd.
  • 18.33. Vertex Pharmaceuticals Incorporated
  • 18.34. Viatris Inc.
  • 18.35. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIRECT ACTING ANTIVIRALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GLECAPREVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GLECAPREVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GLECAPREVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VOXILAPREVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VOXILAPREVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VOXILAPREVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY LEDIPASVIR SOFOSBUVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY LEDIPASVIR SOFOSBUVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY LEDIPASVIR SOFOSBUVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VELPATASVIR SOFOSBUVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VELPATASVIR SOFOSBUVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VELPATASVIR SOFOSBUVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DASABUVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DASABUVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DASABUVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SOFOSBUVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SOFOSBUVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SOFOSBUVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3 4A NS5A, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3 4A NS5A, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3 4A NS5A, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A NS5B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A NS5B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A NS5B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 217. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 218. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 223. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. GCC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 260. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 261. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 262. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. G7 DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 269. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 270. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 271. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 273. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 274. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 275. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. NATO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)